Back to Top Skip to main content

Case Report: Tick-borne Encephalitis Virus Infection in Beneficiaries of the U.S. Military Healthcare System in Southern Germany

A paratrooper with 1st Squadron, 91st Cavalry Regiment, 173rd Airborne Brigade lies concealed in a forest and observes his target during a combined sniper exercise with the British Army's 1st Battalion, Royal Irish Regiment as part of Exercise Wessex Storm at the 7th Army Joint Multinational Training Command's Grafenwoehr Training Area, Germany, July 30, 2015. Wessex Storm is an annual maneuver exercise for British forces, integrating NATO allies and partners. (U.S. Army photo by Visual Information Specialist Gertrud Zach/released) A paratrooper with 1st Squadron, 91st Cavalry Regiment, 173rd Airborne Brigade lies concealed in a forest and observes his target during a combined sniper exercise with the British Army's 1st Battalion, Royal Irish Regiment as part of Exercise Wessex Storm at the 7th Army Joint Multinational Training Command's Grafenwoehr Training Area, Germany, July 30, 2015. Wessex Storm is an annual maneuver exercise for British forces, integrating NATO allies and partners. (U.S. Army photo by Visual Information Specialist Gertrud Zach/released)

Recommended Content:

Medical Surveillance Monthly Report

ABSTRACT

Tick-borne encephalitis (TBE) is caused by a flavivirus usually transmitted to humans via the bite of an infected Ixodes ricinus tick. The disease is endemic to central Europe, including Germany where it is a potential threat to U.S. service members and other beneficiaries. This report describes 3 cases of TBE in persons living during 2017 and 2018 in the region of Germany with the highest incidence of TBE: a 36-year-old active duty service member and 2 non-service member beneficiaries aged 17 and 7 years. Each patient presented with debilitating symptoms and, following recovery from their acute illnesses, experienced troubling sequelae for months afterward. The nature of their initial illnesses varied from one another, as did the length and nature of their sequelae. The criteria for diagnosing TBE based upon clinical symptoms and laboratory test results are described. Preventive strategies for protecting residents in Germany from TBE include measures to avoid tick bites. The potential for use of the TBE virus vaccine, not Food and Drug Administration-approved in the U.S. but available in Europe, is discussed.

BACKGROUND

Tick-borne encephalitis (TBE) is caused by tick-borne encephalitis virus (TBEV), a flavivirus distributed throughout Eurasia. Germany has a relatively high incidence of TBE; in 2016, Germany reported 348 of the 1,534 total cases reported in Europe.1 There are 3 TBEV subtypes; the subtype most prevalent in Germany is the European subtype, most commonly transmitted by the tick Ixodes ricinus. Rarely, TBEV can be transmitted through the ingestion of contaminated dairy products, such as unpasteurized milk.2 TBE (known as Frühsommer-Meningoenzephalitis in German) can cause debilitating meningoencephalitis and long-term sequelae; as such, it poses a health threat to U.S. service members and beneficiaries residing in Germany.3

Typical risk factors for TBE include living in a known risk area and engaging in activities in wooded/forested areas, such as hiking, camping, mushroom gathering, and military field exercises.4,5 About half of patients diagnosed with TBE recall a tick bite.6 The majority of TBE cases are among males, in both pediatric and adult populations.7–9

TBEV infection can cause a spectrum of illness ranging from subclinical (about one-third of cases) to death (0–1.4%).2 Differences in clinical severity are believed to be due to varying virulence of the pathogen and individual factors, most prominently age (older age is associated with increased severity of disease) and comorbidities (especially immunosuppresion).1 Presentation is typically biphasic (72–87% of patients), with a generally subclinical, viremic prodromal phase followed by a more severe second phase. The early phase is characterized by non-specific symptoms such as fever, anorexia, muscle aches, nausea, and vomiting.10 The most common laboratory findings during the first phase of TBE include leukopenia and thrombocytopenia. It is estimated that 30–50% of symptomatic TBE patients experience only the initial phase of illness, while the remainder experience both phases.1 Remission between the first and second phases typically lasts about 8 days. The second phase of TBE involves the central nervous system. Patients may have symptoms of meningitis (fever, headache, neck stiffness), encephalitis (drowsiness, confusion, sensory or motor disturbance), or meningoencephalitis.10 The most common laboratory findings during the second phase include an elevated white blood cell count, white blood cells in the cerebrospinal fluid (CSF), and increased protein in the CSF. It is common to see an initial predominance of granulocytes in CSF that shifts to a predominance of lymphocytic cells later in the illness. An abnormal electroencephalogram (EEG) is seen in 77% of patients.1 Sequelae following acute infection are relatively common; 26–46% of patients reported some form of remaining symptoms, such as headache and difficulties with concentration or memory, 6–12 months following acute infection.2

The current report describes 3 cases of TBE that occurred among U.S. Military Health System beneficiaries living in Germany in 2017 and 2018. A large portion of this U.S. population resides in Bavaria and Baden-Wurttemberg, the German states where 80–90% of German TBE cases occur. There is 1 large U.S. military installation located in a county (“Landkreis” in German) that consistently reports some of the highest incidence rates of TBE in Germany.11 Cases of TBE described here were identified through the U.S. military’s reportable medical event reporting system—the Disease Reporting System internet (DRSi)—and case details were extracted from Armed Forces Health Longitudinal Technology Application (AHLTA) electronic medical records. Case ascertainment also used inpatient documents from German hospitals, translated and scanned into AHLTA. Individuals were included as cases if they met the European Centre for Disease Prevention and Control (ECDC) definition of TBE requiring 1) clinically apparent disease of the central nervous system and 2) valid laboratory documentation of current TBEV infection in the patient. ECDC laboratory criteria for confirmation of current TBEV infection include at least 1 of the following 5: TBE-specific immunoglobulin M and G (IgM and IgG, respectively) antibodies in blood, TBE-specific IgM antibodies in CSF, seroconversion or 4-fold increase of TBE-specific antibodies in paired serum samples, detection of TBE viral nucleic acid in a clinical specimen, or isolation of TBEV from a clinical specimen.3,12 Diagnosis with TBE-specific IgM and IgG antibodies in blood is the most common method of laboratory confirmation in Germany given the clinical course of TBE (IgM and IgG last longer in serum than the virus does) and clinical simplicity (a single serum sample is easier to draw than CSF or multiple sera samples).13

Case 1

In November 2017, a 36-year-old male, active duty service member presented to a German hospital with fever and delirium. The patient had no known history of a tick bite and was unimmunized against TBE. The patient lived and worked near Hohenfels, Bavaria, Germany, and was frequently in forested, woody, and grassy areas (always in the local region) as part of his military duties.

A companion reported that the patient had experienced fever for approximately 1 week, altered personality at work (including falling asleep there), and left-sided hemiparesis, which appeared on the day of presentation. This is consistent with the published literature, with focal, unilateral, and upper body areas being the most commonly affected by neurological abnormalities, when present.1 At the hospital, the patient complained of headaches, retrobulbar pain, and recurring numbness of the left arm and exhibited several episodes of confusion. Rash (not further described in the hospital record) was noted on physical exam.

The patient was too agitated for lumbar puncture (LP) to be performed; accordingly, he was sedated, after which LP was successful. CSF showed moderate pleocytosis consistent with viral meningoencephalitis. An EEG showed a moderately severe, generalized alteration with encephalitic involvement due to known meningitis.

Initially admitted to intensive care, the patient was moved to regular care as he improved. The patient had persistent headaches and what the hospital record described as “general psychomotor slowing and reactions.” Upon admission, the patient was promptly treated with antibacterial and antiviral medications, initially ampicillin, acyclovir, and ceftriaxone. As results of testing became available, the antimicrobials were stopped in a stepwise manner. The patient was diagnosed with TBE on the basis of the compatible clinical presentation and positive serum TBE IgG and IgM antibodies. The patient gradually improved over 10 days of hospitalization. Upon discharge, 2 weeks of rest at home were recommended.

Following discharge, this soldier reported generalized fatigue, weakness in arms and shoulders, imbalance, headaches, and trouble with memory/focus lasting for several months. Although the fatigue and weakness gradually improved after 4–5 months, headaches persisted for over 6 months. These symptoms mostly resolved; however, he reported intermittent difficulties with memory, focus, and persistent headaches.

Case 2

In June 2018, a 17-year-old male presented to a U.S. military hospital emergency department (ED) with right-sided frontal headache. The patient lived near Stuttgart, Baden-Wurttemberg, Germany. The patient noted no tick bite, was unimmunized for TBE, and reported no pertinent outdoor activities. He had a multiyear history of recurrent headaches and reported that his current headache was greater in intensity but in the same location as previous headaches. The patient denied nausea, vomiting, sensitivity to light or sounds, numbness, focal weakness, stiff neck, and fever. He was treated with intramuscular ketorolac (an antiinflammatory drug used to treat pain), intravenous fluids (IV), and IV antiemetics. Computed tomography (CT) scan showed no acute abnormalities. The patient improved significantly with treatment and was diagnosed with tension headache, prescribed butalbital/acetaminophen/caffeine, and released from the ED.

The following day, the patient presented to his regular outpatient clinic for a recommended follow-up. Since discharge from the ED, he had developed fever (39.3°C), worsened headache, neck stiffness, vomiting, photophobia, muscle aches, and dizziness. He reported having a cold recently, but symptoms of his cold had reportedly resolved before the onset of the headache and were mild enough that he did not seek care for them. These symptoms could be consistent with biphasic presentation, reported in about 80% of cases in Germany.1

The patient was referred to a local German hospital and admitted for possible meningitis. Upon presentation, he was still febrile (39.7°C), with meningismus and mild throat inflammation. Blood tests showed leukocytosis, elevated C-reactive protein, and low overall IgG. CSF showed leukocytosis, pleocytosis, and increased protein. Magnetic resonance imaging (MRI) showed no evidence of meningitis or encephalitis. Chest x-ray findings were consistent with bronchopneumonia with left basal consolidation. Urinalysis was positive for protein, ketones, bilirubin, and urobilirubin. An EEG was normal.

On the third day of hospitalization, the patient had low oxygen saturation values (down to 84%) and was transferred to intensive care. The following day, the patient’s oxygen saturation improved and he was transferred back to regular care.

Upon admission, the patient was promptly treated with antibacterial and antiviral medications (initially ampicillin, acyclovir, ceftriaxone) and analgesia (ibuprofen, paracetamol, metamizole, and tramadol). On the same day as his intensive care unit transfer, the patient received a one-time, high dose of systemic corticosteroids. He was diagnosed with TBE based on his clinical presentation and positive serum TBE IgG and IgM antibodies. Of note, there was no evidence of TBE IgG or IgM in the CSF.

Following 9 days of hospitalization with gradual improvement, the patient was discharged from the hospital in stable condition. After discharge, the patient experienced fatigue that was disruptive to his work and led to medical follow-up. The fatigue persisted for approximately 3 months before complete resolution.

Case 3

In September 2018, a 7-year-old female developed worsening headache, photophobia, fever (reported 40°C), nausea, vomiting, and diarrhea over 2 days. She lived near Stuttgart, Baden-Wurttemberg, Germany, and was unimmunized against TBE. Her family reported hiking in Germany twice (in May and September of 2018), with no known tick bite or other pertinent travel. Outpatient evaluation yielded a diagnosis of unspecified viral illness for which she was prescribed oral rehydration therapy and antipyretics. Of note, nausea and vomiting are common presenting symptoms of TBE, especially among pediatric patients.9

Upon outpatient follow-up the next day, the patient had experienced no improvement. The patient’s parents were instructed to go to a local German hospital, where the patient was admitted with the complaints described above and neck stiffness. On hospital day 1, her condition continued to deteriorate.

LP was performed on hospital day 1. The patient’s CSF showed pleocytosis, leukocytosis, and an increased albumin ratio, indicative of a breakdown in the blood-brain barrier consistent with meningitis. The patient’s CSF had a positive TBE IgG index. The TBE IgG index is a diagnostic calculation that compares TBE IgG concentrations in the CSF to TBE IgG concentrations in the serum, controlling for total IgG concentrations in both the CSF and serum. A positive TBE IgG index (higher levels of TBE IgG in the CSF than in the serum) demonstrates intrathecal production of TBE antibodies, an indicator of active TBE infection.13 Serum was positive for TBE IgG and IgM. Of note, serum was also IgM positive for herpes simplex virus and enterovirus; however, upon expert consultation, no other good evidence for another (non-TBE) etiology was found among the diseases for which the patient was tested, and this case is consistent with a typical TBE infection in childhood (G. Dobler, MD, Lt Col, Bundeswehr, email communication, 09 April 2019).

An EEG (hospital day 3) was abnormal with right temporo-parieto-occipital slowing and a one-time spike-wave complex on the right frontal side. MRI (hospital day 3) showed prominent superficial cranial vessels and sphenoidal and maxillary sinusitis but no evidence of encephalitis. An EEG (hospital day 7) was normal.

Despite aggressive antipyretic treatment, the patient had persistent fevers during the first 4 inpatient days (ranging between 38° and 40°C) before defervescing on hospital day 4. She received IV glucose/electrolyte solutions for 7 days. Upon admission, she was promptly treated with antibacterial and antiviral medications, initially ampicillin, acyclovir, and ceftriaxone. There appears to have been no significant delay in treatment or diagnosis in this case.

Following 8 days of hospitalization, the patient was discharged in stable condition. Following hospital discharge she suffered significant difficulties with focus (in general) and school. Before infection, she was doing better in school than a twin sister. After infection, her twin was doing better and the patient had significant school difficulties. As of March 2019, the patient continued to have persistent, periodic headaches and to be much less energetic than before the infection. She was reported to be much more socially withdrawn.

The patient was unimmunized against TBE; however, 1 week before the patient first developed symptoms, her family had contacted the military clinic to seek TBE vaccination. The referral process was started; however, given multiple steps in the process, the actual appointment for vaccination with a German clinic was set for 3–4 weeks later. In the interim, the patient developed TBE.

EDITORIAL COMMENT

Although cases of TBE among U.S. travelers to Europe and Asia have been described previously, this is the first report to describe such cases among U.S. service members and beneficiaries living in Europe.14 The cases illustrate the significant acute debilitation that TBE can cause. For example, case 1, an active duty soldier, experienced dramatically altered mental status, the most common neurological symptom.1 TBE infection in this patient caused a 10-day hospitalization, 2 weeks of convalescence, and months of headaches, decreased energy, and difficulty with concentration; ultimately, there was a significant negative impact on his readiness and deployability. Moreover, all patients reported some degree of sequelae following resolution of TBEV infection, which is well described in the literature.1,8 For example, case 3 (a 7-year-old female) experienced cognitive issues. Pediatric patients often recover physically more quickly from TBE, but cognitive sequelae represent a prominent concern.9 This report also documents that those residing in a risk area (e.g., in Bavaria and Baden-Wurttemberg, Germany) are potentially more likely to contract TBE. Two of 3 cases reported participation in traditionally high-risk outdoor activities; however, none recalled a tick bite.

These cases also highlight the potential for underdiagnosis of TBE in the U.S. population stationed in Germany. Underdiagnosis occurs in the European healthcare system and is thought to be due to lack of knowledge of the disease and the relative rarity of “classical” clinical presentation of TBE.5 If TBE is underdiagnosed by European providers, it is likely also underdiagnosed by U.S. providers in Europe. Lack of education and awareness of this Eurasian zoonosis could preclude its consideration in a differential diagnosis. Furthermore, there are challenges accessing diagnostics in the U.S. healthcare system. Serum testing for TBE IgG and IgM is available; however, it is not included as a standard test and requires direct coordination with the laboratory and a specific request for the test. Failure to appropriately diagnose TBE could lead to unnecessary testing, the lack of a definitive diagnosis, and an unclear prognosis. Such uncertainty might prevent a patient from accessing or utilizing appropriate specialty services during and after the acute phase of the disease. Delays in diagnosis could also contribute to similar problems. Although cases 2 and 3 did have to visit a U.S. provider twice before referral, review of the clinical details (especially the lack of meningeal signs during the first visit for both) suggest there was no delay in appropriate referral to the German system; similarly, there appears to be no delay in appropriate diagnosis once in the German system.

Efforts should be made to prevent TBE in the U.S. military population in Europe. These efforts could mirror the German, Austrian, or World Health Organization (WHO) public health approaches, which include promoting avoidance of ticks/TBE (i.e., through behavior, appropriate clothing, repellants, and early detection of ticks) and vaccination (either targeted or in the general population).5 The Austrian national government recommends and financially supports generalized vaccination for all residents.15 German military personnel are all required to receive TBE vaccine in order to be prepared to support national emergency response efforts in endemic areas (K. Erkens, MD, Lt Col, Bundeswehr, email communication, 13 November 2019). The WHO recommends vaccination of all age groups in areas of high pre-vaccination prevalence (defined as = 5/100,000 per year).16,17 The German government recommends vaccination for all individuals 1 year or older in risk areas defined by the Robert Koch Institute.3 One study showed overall TBE vaccination in Germany at 27%, with higher rates in the highest-risk areas (i.e., 37–40% in Bavaria and Baden-Wurttemberg).18

None of the cases reported here had been immunized against TBEV. Vaccination is safe and effective in preventing TBE. Unfortunately, no TBE vaccines are U.S. Food and Drug Administration (FDA) approved, so purchase or administration by the U.S. government, including U.S. military medical facilities, is legally restricted. Administration of TBE vaccine is, however, now covered by insurance for U.S. military members in Europe. It is administered only at the level of individual patients, not at the level of military units or as a public health effort. Through the efforts of the European Command (EUCOM) and medical providers in Germany, TBE vaccine was approved for all active duty beneficiaries through TRICARE Eurasia in May 2014. Before that (starting in February 2008), it was identified as a TRICARE eligible benefit for dependents and retirees. Currently, obtaining TBE vaccination among the U.S. military population requires a multistep process. The patient must first visit their military provider, who verifies the patient will be in country long enough to complete the series (at least 1 year longer). A referral to a German provider is then made. The patient then makes an appointment and visits the German provider. The patient receives the initial dose then arranges to receive the additional doses 3 and 9 months later. Given the requirement to obtain a special referral and arrange for and make multiple visits to an off-post provider, it is possible this process is sufficiently onerous to deter some from seeking the vaccine. Department of Defense (DoD) civilian employees with private (non-TRICARE) health insurance receive healthcare through the German medical system. Accordingly, for DoD civilians, TBE vaccine has been covered for as long as it has been standard of care in the German healthcare system.

Also, because the vaccine is not offered through the U.S. Military Health System or as part of any force health protection efforts, it is possible that U.S. military personnel may simply not be aware of the vaccine or indications for seeking it. There have been efforts by EUCOM and the Defense Health Agency to obtain FDA approval for TBE vaccine. FDA approval would likely simplify the process of obtaining vaccine and would allow it to be considered as a force health protection and/or public health measure. For example, the U.S. military could explore mirroring the German military model of requiring TBE vaccination for all military personnel stationed in Bavaria and Baden-Wurttemberg. Cost-benefit analysis of TBE vaccination of U.S. military personnel would inform this consideration.

This case study has several limitations. Many clinical details were derived from German medical records; all were translated by certified medical translators in an approved but imperfect process. Sequelae and preceding symptoms were ascertained up to a year after TBE infection and were likely subject to recall bias.

U.S. Military Health System beneficiaries living in Germany are at risk of TBE. It is important for providers caring for military service members in Europe to be proficient in the recognition and treatment of TBE. The U.S. military healthcare system in Europe should educate providers and patients regarding TBE risk, prevention, diagnosis, and treatment. The U.S. military healthcare system should also strive to make TBE diagnostics readily available to its providers and beneficiaries either internally or through enhanced cooperation with the German healthcare system.


Author affiliations: U.S. Army Medical Department Activity-Bavaria, Department of Preventive Medicine (LTC Mease, MAJ Maddox, Ms. Whitman); Madigan Army Medical Center (LTC Mease); Fort Hood Public Health (MAJ Maddox); 18th Military Police Brigade (MAJ Noss)

Acknowledgments: The authors thank Prof. Dr. Gerhard Dobler (Lt Col, Bundeswehr) for his thoughtful consultation, MAJ Daniel Weinstein for his valuable operational perspective, Mr. Joey Scaletta for his consistent support, and COL James Mancuso for his excellent guidance.

Funding: All work described herein was performed as part of paid regular duties as part of employment by the U.S. Government.

Disclaimer: The views expressed are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense, or the U.S. Government.


REFERENCES

1. Erber W, Schmitt H-J, Vukovic Jankovic T. Epidemiology by country—an overview. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:114–127.

2. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861–1871.

3. Borde JP, Zajkowska J. TBE in adults. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encepahlitis (TBE). Singapore: Global Health Press;2018:70–85.

4. European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE). https://ecdc.europa.eu/en/tick-borneencephalitis/facts/factsheet. Accessed 28 August 2019.

5. Kunze M, Haditsch M. TBE as a matter of public health. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:283–289.

6. Hellenbrand W, Kreusch T, Bohmer MM, et al. Epidemiology of tick-borne encephalitis (TBE) in Germany, 2001–2018. Pathogens. 2019;8(2).

7. Dobler G, Tkachev S. General epidemiology of tick-borne encephalitis. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:103–113.

8. Logar M, Arnez M, Kolbl J, Avsic-Zupanc T, Strle F. Comparison of the epidemiological and clinical features of tick-borne encephalitis in children and adults. Infection. 2000;28(2):74–77.

9. Sundin M. TBE in children. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:85–91.

10. Centers for Disease Control and Prevention. Tick-borne encephalitis: signs and symptoms. https://www.cdc.gov/vhf/tbe/symptoms/index.html. Accessed 27 August 2019.

11. Mackenstedt U, Dobler G. TBE in Germany. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:170–174.

12. European Centre for Disease Prevention and Control. Surveillance and disease data for tickborne encephalitis. https://ecdc.europa.eu/en/tickborne-encephalitis/surveillance-and-disease-data. Accessed 20 May 2019.

13. Dobler G. Diagnosis. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:276–282.

14. Centers for Disease Control and Prevention. Tick-borne encephalitis among U.S. travelers to Europe and Asia—2000–2009. MMWR Morb Mortal Wkly Rep. 2010;59(11):335–338.

15. Heinz FX, Stiasny K, Holzmann H, et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis. 2013;19(1):69–76.

16. Poellabauer EM, Kollartisch H. Prevention—vaccines and immunoglobulins. In: Dobler G, Erber W, Schmitt H-J, eds. Tick-Borne Encephalitis (TBE). Singapore: Global Health Press;2018:290–304.

17. World Health Organization. Vaccines against tick-borne encephalitis: WHO position paper—recommendations. Vaccine. 2011;29(48):8769–8770.

18. Erber W, Schmitt H-J. Self-reported tick-borne encephalitis (TBE) vaccination coverage in Europe: results from a cross-sectional study. Ticks Tick Borne Dis. 2018;9(4):768–777.


You also may be interested in...

Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency, U.S. Armed Forces, May 2004–September 2018

Article
12/1/2019
Staff Sgt. Cory Gage, 23d Medical Support Squadron medical laboratory technician, places a blood specimen in an automated hematology analyzer, Aug. 29, 2017, at Moody Air Force Base, Ga. Moody’s lab technicians process blood to check for a variety of cell abnormalities from infections to cancer. (U.S. Air Force photo by Airman 1st Class Erick Requadt)

Recommended Content:

Medical Surveillance Monthly Report

Case Report: Hansen’s Disease in an Active Duty Soldier Presenting with Type 1 Reversal Reaction

Article
12/1/2019
Ulcer along the interspace between the patient’s right index and middle fingers. Photograph courtesy of Brooke Army Medical Center Medical Photography.

Recommended Content:

Medical Surveillance Monthly Report

Positive Predictive Value of an Algorithm Used for Cancer Surveillance in the U.S. Armed Forces

Article
12/1/2019
Naval Hospital Jacksonville physicians Lt. Catherine Perrault, right, and Lt. Joseph Sapoval review patient charts at the hospital’s labor and delivery unit. Perrault, from Orlando, Florida, rendered aid at the scene of an accident involving a train and a school bus on Sept. 27, 2018. Perrault recently returned from a deployment to the Middle East where she served as the general medical officer aboard the amphibious assault ship USS Iwo Jima (LPH 2). During the deployment, she provided routine, acute, and critical care. (U.S. Navy photo by Jacob Sippel/Released)

Recommended Content:

Medical Surveillance Monthly Report

Update: Gallbladder Disease and Cholecystectomies, Active Component, U.S. Armed Forces, 2014–2018

Article
12/1/2019
Hansen's disease nerve

Recommended Content:

Medical Surveillance Monthly Report

Tick-borne encephalitis surveillance in U.S. military service members and beneficiaries, 2006–2018

Article
11/1/2019
©ECDC/Photo by Guy Hendrickx

Recommended Content:

Medical Surveillance Monthly Report

Editorial: Mitigating the Risk of Disease From Tick-borne Encephalitis in U.S. Military Populations

Article
11/1/2019
Female Ixodes ricinus Tick ©ECDC/Photo by Francis Schaffner

Recommended Content:

Medical Surveillance Monthly Report

Update: Cold Weather Injuries, Active and Reserve Components, U.S. Armed Forces, July 2014–June 2019

Article
11/1/2019
A U.S. Marine with Marine Rotational Force-Europe (MRF-E) 19.1 maintains a defensive security position during Exercise Winter Warrior in Haltdalen, Norway, Dec. 5, 2018. The three-week exercise tested the Marines' abilities to adapt to harsh weather conditions, move across long distances in the snow and push themselves to complete the mission despite austere situations. (U.S. Marine Corps photo by Cpl. Elijah Abernathy/Released)

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Influenza Immunization Among U.S. Armed Forces Healthcare Workers, August 2014–April 2019

Article
10/1/2019
181129-N-GR847-3000 ARABIAN GULF (Nov. 29, 2018) Hospitalman Jay Meadows, from Weaver, Ala., administers an influenza vaccine to a Sailor during a regularly scheduled deployment of the Essex Amphibious Ready Group (ARG) and 13th Marine Expeditionary Unit (MEU). The Essex ARG/13th MEU is flexible and persistent Navy-Marine Corps team deployed to the U.S. 5th Fleet area of operations in support of naval operations to ensure maritime stability and security in the Central Region, connecting to the Mediterranean and the Pacific through the western Indian Ocean and three strategic choke points. (U.S. Navy photo by Mass Communication Specialist 3rd Class Reymundo A. Villegas III)

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Trends in Opioid Prescription Fills Among U.S. Military Service Members During Fiscal Years 2007–2017

Article
10/1/2019
U.S. Air Force Tech Sgt. Ryan Marr, 18th Medical Group pharmacy craftsman, processes prescriptions, June 8, 2018, at Kadena Air Base, Japan. The pharmacy processes and fills prescriptions for hundreds of different medical needs. (U.S. Air Force photo by Staff Sergeant Jessica H. Smith) Merriam/Released)

Recommended Content:

Medical Surveillance Monthly Report

Measles, Mumps, Rubella, and Varicella Among Service Members and Other Beneficiaries of the Military Health System, 1 January 2016–30 June 2019

Article
10/1/2019
U.S. Air Force Airmen of the 163d Attack Wing line up to  receive a flu vaccine at March Air Reserve Base, California, Nov. 4, 2018. The flu vaccine is an annual requirement for military members to help curb the spread of the flu and limit its impact within the unit. (U.S. Air National Guard photo by Tech. Sgt. Julianne M. Showalter)

Recommended Content:

Medical Surveillance Monthly Report

Animal Bites and Rabies Post-exposure Prophylaxis, Active and Reserve Components, U.S. Armed Forces, 2011–2018.

Article
10/1/2019
Big Brown Bat stock photo (iStock.com)

Animal Bites and Rabies Post-exposure Prophylaxis, Active and Reserve Components, U.S. Armed Forces, 2011–2018

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Temporal Presentation of Visual Dysfunction Following Diagnosis of Traumatic Brain Injury, Active Component, U.S. Armed Forces, 2006–2017

Article
9/1/2019
SAN DIEGO (April 6, 2017) Cmdr. John Cason, program director Navy Refractive Surgery, performs the second Small Incision Lenticular Extraction (SMILE) procedure at Naval Medical Center San Diego. The SMILE procedure is the latest advancement in refractive surgery for correcting myopia or nearsightedness. (U.S. Navy photo by Mass Communication Specialist 1st Class Elizabeth Merriam/Released)

Recommended Content:

Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens Attributable to Ocular and Vision-Related Conditions, Active Component, U.S. Armed Forces, 2018

Article
9/1/2019
Senior Airman Breanna Daniels, 559th Medical Group optometry technician, takes images of Tech. Sgt. Stephanie Edmiston, 559th MDG trainee health flight chief, during an eye exam Oct. 19 at the Reid Clinic on Joint Base San Antonio-Lackland, Texas. The 559th MDG is home to the largest optometry and public health flight in the Department of Defense; the DOD's first military training consultation service. (U.S. Air Force photo/Staff Sgt. Kevin Iinuma)

Recommended Content:

Medical Surveillance Monthly Report

Editorial: The Department of Defense/Veterans Affairs Vision Center of Excellence

Article
9/1/2019
U.S. Army Spc. Angel Gomez, right, assigned to Charlie Company, 173rd Brigade Support Battalion, wraps the eye of a fellow Soldier with a simulated injury, for a training exercise as part of exercise Saber Junction 16 at the U.S. Army’s Joint Multinational Readiness Center in Hohenfels, Germany, April 5, 2016. Saber Junction is a U.S. Army Europe-led exercise designed to prepare U.S., NATO and international partner forces for unified land operations. The exercise was conducted March 31-April 24. (U.S. Army photo by Pfc. Joshua Morris)

Recommended Content:

Medical Surveillance Monthly Report

Incident and Recurrent Cases of Central Serous Chorioretinopathy, Active Component, U.S. Armed Forces, 2001–2018

Article
9/1/2019
A phoropter is an instrument used to determine an individual’s eyeglass prescription by measuring the eye’s refractive error and switching through various lens until the persons vision is normal. (U.S. Air Force photo by Airman Dennis Spain)

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5 > >> 
Showing results 1 - 15 Page 1 of 5

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.